Indian biomedicine will grow at an annual growth rate of US $ 3.5 billion last year
Release time: 2011-11-24 stake online sports bettingStake Sports Betting& nbsp & nbsp & nbsp Source:
The website of the Ministry of Science and Technology has published a message a few days ago，A senior person in Indian biotechnology industry said，From biopharmaceutical、Biotechnology and vaccine's growing demand for the growing needs，Indian biotechnology industry in the near future is expected to reach 20%in the future。
President and Managing Director of BIOCON Company, the most operating income of India, Kilan Sujie. Xiao said: "We are entering the biological economy era。Now we are facing severe challenges: food shortage，Energy shortage，Environmental destruction，Can't meet medical needs，There is also industrial pollution，and biotechnology can provide a powerful solution。"Bio -fuel also provides a huge growth opportunity for biotechnology。
She said，The scale of the Indian biotechnology industry has reached 3.5 billion US dollars in 2010，and is expected to grow strongly in various areas of biotechnology。"India in vaccine production、GM cotton and biopharmaceuticals，Especially for biological generic drugs, it has lived in the world's leading position。India is also a big producer in terms of industrial enzymes required for green technology and biological repair。We are huge in the planting of organizational training。”
She also talked about the lag of supervision，Export and export delay and restrictions，Lack of unfavorable factors such as entrepreneurial funds and regulating listing，Impact of the development of biotechnology companies dominated by innovation。"The internal risk during stake online sports bettingstake sports betting appthe breeding process of biotechnology products is a huge test of investors。GM eggplant is an example。”
When asked about the prospects of BIOCON, headquartered in Bangalore,，The president of the 100 most influential figures in the world by Time Magazine said: "The strategic goal I am committed to pursuing is to provide a affordable drug to the global market，Different medical services。"(Reporter Cui Lei)
President and Managing Director of BIOCON Company, the most operating income of India, Kilan Sujie. Xiao said: "We are entering the biological economy era。Now we are facing severe challenges: food shortage，Energy shortage，Environmental destruction，Can't meet medical needs，There is also industrial pollution，and biotechnology can provide a powerful solution。"Bio -fuel also provides a huge growth opportunity for biotechnology。
She said，The scale of the Indian biotechnology industry has reached 3.5 billion US dollars in 2010，and is expected to grow strongly in various areas of biotechnology。"India in vaccine production、GM cotton and biopharmaceuticals，Especially for biological generic drugs, it has lived in the world's leading position。India is also a big producer in terms of industrial enzymes required for green technology and biological repair。We are huge in the planting of organizational training。”
She also talked about the lag of supervision，Export and export delay and restrictions，Lack of unfavorable factors such as entrepreneurial funds and regulating listing，Impact of the development of biotechnology companies dominated by innovation。"The internal risk during stake online sports bettingstake sports betting appthe breeding process of biotechnology products is a huge test of investors。GM eggplant is an example。”
When asked about the prospects of BIOCON, headquartered in Bangalore,，The president of the 100 most influential figures in the world by Time Magazine said: "The strategic goal I am committed to pursuing is to provide a affordable drug to the global market，Different medical services。"(Reporter Cui Lei)
